Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Adam Winstock

28 papers in the library · 841 citations · publishing 2006-2026

Papers

Ketamine: reclassification alone will not reduce harms

BMJ February 3, 2026 Adam Winstock, David Nutt, Caroline S Copeland

Reclassifying ketamine without accompanying public health measures would be a symbolic action rather than an effective strategy for reducing harm, according to the authors. They argue that regulatory changes alone are insufficient and must be paired with broader public health interventions to meaningfully address risks associated with ketamine use.

Psychedelics and Sexual Trauma: Effects on Communication and Emotional Connection.

Journal of sex research January 16, 2026 Mason Levey, Benjamin Bonenti, Timothy Piatkowski et al.

People who reported having used psychedelics to cope with or overcome sexual trauma were significantly less likely to say the drugs improved their sexual communication compared to those who had not used psychedelics for that purpose. No significant difference was found in emotional connection between the two groups. Among those who had used psychedelics for trauma, women were significantly more likely than men to report improvements in both communication and emotional connection. The findings suggest that gender plays a role in how psychedelics affect intimacy, and more research is needed to guide harm reduction and trauma-informed care.

The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample.

Journal of psychopharmacology (Oxford, England) August 1, 2014 Will Lawn, Monica J Barratt, Martin L Williams et al.

NBOMe compounds are a new series of potent hallucinogenic drugs that activate the 5-HT2A receptor. An anonymous online survey in 2012 with 22,289 respondents found that 2.6% (582 people) had ever tried one of three NBOMe drugs, with 25I-NBOMe being the most popular at 2.0% (442 people). Nearly all (93.5%) who last tried a NBOMe drug did so in 2012, and 81.2% administered it orally or sublingually. Subjective effects resembled other serotonergic hallucinogens, but users reported higher negative effects while high and greater value for money. The most common source (41.7%) was a website. NBOMe drugs are recently emerged, often bought online, and may pose larger risks due to limited knowledge, low price, and internet availability.